Getting the diagnosis of chronic myeloid leukemia, Bud
Interviewee: Bud. Bud recounts receiving the diagnosis that he had chronic myeloid leukemia. (DNAi Location: Applications > Genes and medicine > Drug design > Bud's Story > "A death sentence")
It was devastating there I didn't know what to do, you know, that's a death sentence. Was then. It was a death sentence. They gave me two or three years is what he gave me and that was eight years ago. I've been into it five now out of eight. So I beat it by five so far but of course that's, you know what it is, Gleevec�„� there has helped me out.
chronic myeloid leukemia,location applications,gleevec,dnai,romine,death sentence,cml,interviewee,leukemia,bud,genes,diagnosis,medicine
- ID: 15041
- Source: DNALC.DNAi
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.
Yvonne talks about the magic pills Bud took.
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevecâ¢ inhibits the molecular cause of chronic myeloid leukemia.
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
Brian Druker talks about how the drug he designed targets the molecular cause of CML.